Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-105.43M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.95 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -21.65% |
| Return on Assets (Trailing 12 Months) | -20.88% |
| Current Ratio (Most Recent Fiscal Quarter) | 38.51 |
| Quick Ratio (Most Recent Fiscal Quarter) | 38.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.79 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.03 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 66.21M |
| Free Float | 50.66M |
| Market Capitalization | $7.26B |
| Average Volume (Last 20 Days) | 0.78M |
| Beta (Past 60 Months) | -0.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.49% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.44% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |